Press Releases | Takeda Pharmaceuticals
Learn more about Takeda's latest press releases.
Takeda and AC Immune Announce Exclusive Option and License …
May 13, 2024 · Takeda and AC Immune partner for ACI-24.060, an active immunotherapy targeting toxic forms of amyloid beta to potentially slow Alzheimer’s disease progression. Learn more about this groundbreaking treatment approach and …
Takeda Delivers Strong Revenue and Profit Growth in FY2022 …
May 11, 2023 · Takeda today announced strong financial results for fiscal year 2022 delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products.
Takeda Announces Strategic Leadership Changes to Help Drive …
Feb 3, 2022 · Gabriele Ricci, who formerly served as Head of IT for the Plasma-Derived Therapies (PDT) Business Unit has been appointed Takeda’s Chief Data and Technology Officer, effective February 1, 2022. In this role, Gabriele will lead the critical transformation of the company’s Data, Digital and Technology division.
FDA Approves EOHILIA (budesonide oral suspension) | Takeda News
Feb 12, 2024 · FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) February 12, 2024. Share. 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older. EoE Is a Chronic Disease That Can Significantly Impact Patients ...
FDA Approves Subcutaneous Administration of ENTYVIO - Takeda
Apr 18, 2024 · ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease.
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts …
Oct 26, 2023 · OSAKA, Japan, and CAMBRIDGE, Massachusetts, October 26, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Management Guidance for Core growth at Constant Exchange Rate.
US News Releases - Takeda
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Takeda Pharmaceuticals: Global Homepage
Sep 24, 2024 · Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet. Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a …
Takeda Launches Growth Program for Enhanced Profit Margins in …
May 9, 2024 · Discover Takeda's new enterprise-wide initiative aimed at boosting organizational agility and spending efficiency. With a focus on data, digital, and technology, Takeda strives for a core operating profit margin increase and sustainable growth.